In November 2017, Asana Medical, Inc. announced that they had formally changed their name to Regentys, as a more distinctive representation of their business model and underlying regenerative medicine technology.

Regentys Appoints Dr. Steven D. Wexner Chief Medical Officer

Dec. 7, 2017

Regentys (formerly Asana Medical, Inc.) has named Dr. Steven D. Wexner as its Chief Medical Officer (“CMO”). Dr. Wexner has been a member of the Regentys Medical Advisory Board since January 2014.

Read More →

Asana Medical, Inc. Announces Corporate Name Change to Regentys

Nov. 28, 2017

MIAMI LAKES, FL – November 28, 2017 -- Asana Medical, Inc., ("Asana"), a regenerative medicine company developing a novel treatment for Ulcerative Colitis (“UC”), is pleased to announce that it has changed its corporate name to Regentys (“Regentys”, the “Company”). The change, which also includes a new corporate logo and branding platform, reflects the Company’s continuing vision and development of its regenerative medicine technologies portfolio, and its lead product, ExtraCellular Matrix Hydrogel (“ECMH”).

Read More →

Asana Medical, Inc. to Present as Innovation Challenge Finalist at RESI Boston Conference 2017

Sept. 11, 2017

Asana has been selected as an Innovation Challenge Finalist and will present at the RESI Conference in Boston, Massachusetts on Tuesday, September 26th, 2017

Read More →

Dr. Susan G. Manella Joins Asana’s Medical Advisory Board

Aug. 25, 2017

Dr. Susan G. Manella has accepted the Company’s offer to join its Medical Advisory Board. Dr. Manella will assume the board’s leadership role in managing information flow and liaising between management and medical doctors.

Read More →

Pharmaceutical Industry Executive Brian W. Andersen Named Chief Business Officer

April 18, 2017

Brian W. Andersen, an experienced industry executive with a proven record of commercial excellence, has been appointed Chief Business Officer.

Read More →